Skip to main content

Table 1 Mean ± SD, median (IQR), or proportion of the main anthropometric, clinical, functional and radiological variables in the three groups of participants

From: Characterisation of COPD heterogeneity in the ECLIPSE cohort

 

COPD

(n = 2164)

Smoking controls

(n = 337)

Non-smoking controls

(n = 245)

p value

Clinical data

Age (years)

63.4 ± 7.1a, b

55.4 ± 9.0

54.1 ± 9.0

< 0.001

Pack-years

48.6 ± 27.1 a, b

31.6 ± 21.5b

0.2 ± 1.1

< 0.001

Current Smokers (%)

36a

61

 

< 0.001

BMI (kg/m2)

26.5 ± 5.7b

26.8 ± 4.6

27.7 ± 5.4

0.004

FFMI (kg/m2)

17.2 ± 2.8

17.1 ± 2.6

17.2 ± 2.7

0.842

mMRC Score

1.7 ± 1.1 a, b

0.2 ± 0.5b

0.1 ± 0.3

< 0.001

SGRQ-C total score

50.1 ± 20.3 a, b

9.6 ± 12.3b

4.8 ± 6.5

< 0.001

Number of exacerbationsc

0.9 ± 1.2 a, b

0.0 ± 0.1

0.0 ± 0.1

< 0.001

Heart trouble (%)

26 a, b

11

9

< 0.001

Heart attack (%)

9 a, b

3

1

< 0.001

Stroke (%)

4d

2

1

0.018

Heart failure (%)

7 a, b

1

0

< 0.001

Arrhythmia (%)

12a, d

5

7

< 0.001

Osteoporosis (%)

14 a, b

5

5

< 0.001

Diabetes (%)

10b

7

5

0.003

Inflammatory bowel disease (%)

5e

2

4

0.127

Peptic ulcer (%)

11b

7d

3

< 0.001

Reflux/heartburn (%)

27d

29d

19

0.031

Depression requiring tx (%)

17

15

14

0.506

Physiology

FEV1 (% predicted)

48.3 ± 15.8 a, b

108.6 ± 12.0d

114.8 ± 13.9

< 0.001

FEV1/FVC (%)

44.8 ± 11.6 a, b

79.2 ± 5.2d

81.1 ± 5.2

< 0.001

FEV1 reversibility (%)

10.7 ± 13.7 a, b

4.5 ± 5.8d

2.7 ± 4.5

< 0.001

Distance walked (metres)

369 ± 122

   

BODE index

3.2 ± 2.1

   

Imaging

Emphysema (%)

17.6 ± 12.2 a, b

2.4 ± 3.1b

4.1 ± 4.2

< 0.001

  1. ap < 0.01 vs. smoking controls; b< 0.01 vs. non-smoking controls; c In the year prior to study dp < 0.05 vs. non-smoking controls. entry. ep < 0.05 vs. smoking controls. Abbreviations: tx: treatment.